The Role of Oral Antidiabetic Agents and Incretin Mimetics in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|22|3705-3715

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.22, 2014-05, pp. : 3705-3715

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease

By  

Current Pharmaceutical Design, Vol. 19, Iss. 29, 2013-09 ,pp. : 5193-5218

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease

By  

Mini Reviews in Medicinal Chemistry, Vol. 15, Iss. 14, 2015-12 ,pp. : 1187-1194

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs for non-alcoholic fatty liver disease

By Federico Alessandro   Niosi Marco   Vecchio Blanco Camillo Del   Loguercio Carmela  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 145-158

Informa Healthcare

Access to resources Recommend Favorite

Non-alcoholic fatty liver disease: a massive problem

By Day Christopher P  

Clinical Medicine, Vol. 11, Iss. 2, 2011-04 ,pp. : 176-178

Royal College Of Physicians

Access to resources Recommend Favorite

Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome

By  

Current Pharmaceutical Design, Vol. 13, Iss. 21, 2007-01 ,pp. : 2193-2198

Bentham Science Publishers

Access to resources Recommend Favorite